Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

3144 results

Sort By:

A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma

Study ID: NCT07446335
Start Date: 2026-04
End Date: 2029-06
Study Type

Interventional

Study Phase

Phase3

No. of Participants

578

Intervention / Treatment

anlotinib combined with benmelstobart

Toripalimab Combined with Chemotherapy

Sponsor

The First Affiliated Hospital of Zhengzhou University

Source: clinicaltrials.gov

Share:
Add to list

Examining the Health Impact of and Promoting Sitting Light Volleyball in the Greater Bay Area

Study ID: NCT07164508
Start Date: 2026-07-01
End Date: 2029-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

225

Intervention / Treatment

Sitting Light Volleyball Intervention

Group Seated Dance Intervention

Sponsor

Education University of Hong Kong

Source: clinicaltrials.gov

Share:
Add to list

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

Study ID: NCT07454668
Start Date: 2026-06
End Date: 2029-07
Study Type

Interventional

Study Phase

Phase1

No. of Participants

20

Intervention / Treatment

Trastuzumab Deruxtecan

Stereotactic Radiosurgery

Sponsor

Baptist Health South Florida

Source: clinicaltrials.gov

Share:
Add to list

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Study ID: NCT07247097
Start Date: 2026-04-15
End Date: 2035-12-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

160

Intervention / Treatment

Elranatamab (PF-06863135)

Daratumumab and Hyaluronidase-fihj

Lenalidomide

Bortezomib for Injection

Dexamethasone

Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions

Study ID: NCT07421388
Start Date: 2026-04-09
End Date: 2026-06-07
Study Type

Interventional

Study Phase

Phase1

No. of Participants

48

Intervention / Treatment

BR1015-A

BR1015-1

BR1015-2

Sponsor

Boryung Pharmaceutical Co., Ltd

Source: clinicaltrials.gov

Share:
Add to list

A Study of Body Fat Distribution and Airway Mechanics in Healthy Adults

Study ID: NCT07019831
Start Date: 2028-01-01
End Date: 2030-06-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Body positioning

Sponsor

Maurizio F. Cereda, MD

Source: clinicaltrials.gov

Share:
Add to list

Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)

Study ID: NCT07449325
Start Date: 2026-04
End Date: 2027-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

A-FLUX Reducer System

Sponsor

VahatiCor, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..

Study ID: NCT07408908
Start Date: 2026-03-06
End Date: 2027-10-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

48

Intervention / Treatment

ACT100 Injection

Placebo for ACT100

ACT100 Injection

Placebo for ACT100

ACT100 Injection

Placebo for ACT100

ACT100 Injection

Placebo for ACT100

ACT100 Injection

Placebo for ACT100

ACT100 Injection

Placebo for ACT100

Sponsor

Xiamen Amoytop Biotech Co., Ltd.

Source: clinicaltrials.gov

Share:
Add to list

EBOla Post-Exposure Prophylaxis

Study ID: NCT06841614
Start Date: 2026-09
End Date: 2028-08-01
Study Type

Interventional

Study Phase

Phase3

No. of Participants

160

Intervention / Treatment

Ervebo

Models

Sponsor

ANRS, Emerging Infectious Diseases

Source: clinicaltrials.gov

Share:
Add to list

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

Study ID: NCT07144826
Start Date: 2026-03-09
End Date: 2027-07-09
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

161

Intervention / Treatment

Biospecimen Collection

Placebo Administration

Probiotic

Administration Questionnaire

Sponsor

Ohio State University Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list